What Auromedics Pharma does

Eugia US LLC (formerly AuroMedics Pharma LLC) is a US-based generic injectable pharmaceutical company headquartered at 279 Princeton Hightstown Road, East Windsor, New Jersey. Founded in 2011, the company manufactures and distributes an extensive portfolio of generic injectable medications spanning multiple therapeutic classes, including carbapenem and combination antibiotics (meropenem, ertapenem, piperacillin/tazobactam, ampicillin/sulbactam, gentamicin), cardiovascular agents (nicardipine, vasopressin, ephedrine sulfate), chemotherapy agents (fluorouracil, cyclophosphamide), central nervous system treatments (methocarbamol, lidocaine), antifungals (amphotericin B liposome), hematology agents (plerixafor), and other specialty injectables (icatibant, testosterone cypionate, pantoprazole sodium).

The company sells to institutional healthcare buyers through a multi-channel go-to-market comprising direct enterprise field sales (Territory Business Managers), Group Purchasing Organization (GPO) contracts, trade partners, and independent hospital accounts. Customers include acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics across the United States. The value proposition emphasizes high-quality products, competitive pricing, and consistent supply, with a stated focus on in-demand, short-supply generic injectable categories.

In 2024 the company underwent a legal name change from AuroMedics Pharma LLC to Eugia US LLC, aligning with the broader Eugia/Aurobindo pharmaceutical group, launched multiple new injectable products, expanded its sales force with new Territory Business Manager hires, and issued a voluntary nationwide recall of Methocarbamol Injection due to particulate contamination. The company employs 51-100 staff and operates exclusively in the US market under contract/quote-based pricing arrangements with institutional customers.

Name

Auromedics Pharma

Legal name

Eugia US LLC

Website

https://auromedics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Eugia US LLC (formerly AuroMedics Pharma) is a US-based generic injectable pharmaceutical company selling an extensive portfolio of antibiotics, cardiovascular, oncology, and specialty injectables to health systems, GPOs, trade partners, and independent hospitals across the United States.

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic injectable pharmaceuticals
• Hospital drug supply
• Sterile injectable manufacturing
• Generic drug distribution
• Institutional pharmaceutical products

Headquarters

HQ city

Windsor

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Generic Injectable Pharmaceuticals: Eugia US generates revenue through the sale of generic injectable pharmaceutical products to healthcare institutions. Products are sold to health systems, hospitals, long-term care facilities, and outpatient clinics through direct sales and channel partners. The business model centers on providing high-quality, competitively priced generic injectables with consistent supply to the institutional healthcare market.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Auromedics Pharma, now operating as Eugia US LLC (formerly AuroMedics Pharma LLC), is a U.S.-based generic injectable pharmaceutical company. It manufactures and distributes an extensive portfolio of sterile injectable medications across multiple therapeutic classes — including antibiotics, antivirals, cardiovascular, central nervous system, hematology, and chemotherapy agents — to healthcare institutions through direct sales, GPO contracts, and trade partners.

Product overview

Eugia US LLC (formerly AuroMedics Pharma LLC) is a generic injectable pharmaceutical company offering an extensive portfolio of injectable medications. The product portfolio includes antibiotics (Meropenem, Ertapenem, Piperacillin and Tazobactam, Ampicillin and Sulbactam, Gentamicin), antivirals, cardiovascular agents (Nicardipine, Vasopressin, Ephedrine Sulfate), central nervous system medications (Methocarbamol, Lidocaine), chemotherapy agents (Fluorouracil, Cyclophosphamide), specialty injectables (Amphotericin B Liposome, Icatibant, Testosterone Cypionate, Plerixafor, Pantoprazole Sodium). The company serves health system customers, GPOs, trade partners, and independent hospitals through a distribution network, targeting in-demand, short-supply generic injectable products for institutional settings including acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics.

Differentiator

Problem solved

Functional benefit

Products and services

• Icatibant Injection Generic injectable medication for hereditary angioedema, available in 30mg/3mL formulation, supplied to hospital and institutional customers.
• Fluorouracil Injection, USP Antimetabolite chemotherapy agent for cancer treatment, supplied in injectable form to institutional oncology settings.
• Testosterone Cypionate Injection, USP CIII Androgen hormone injection used for hormone replacement therapy, supplied to healthcare institutions.
• Amphotericin B Liposome for Injection Antifungal agent in liposomal formulation for systemic fungal infections, supplied to hospital and institutional customers.
• Vasopressin Injection USP Hormone injection at 20 Units per mL, used for vasopressor therapy in critical care settings.
• Ephedrine Sulfate Injection, USP Sympathomimetic agent in 50mg/1mL concentration, used for blood pressure support during anesthesia.
• Cyclophosphamide Injection Alkylating agent chemotherapy medication supplied to hospital oncology settings.
• Nicardipine HCl Injection, USP Calcium channel blocker injectable used in hypertensive emergencies, supplied to hospital customers.
• Ertapenem for Injection Carbapenem antibiotic for complex intra-abdominal infections and other bacterial infections.
• Meropenem for Injection Carbapenem antibiotic for complicated infections, supplied to hospital and institutional customers.
• Piperacillin and Tazobactam for Injection Combination beta-lactam and beta-lactamase inhibitor antibiotic injectable for institutional use.
• Lidocaine Hydrochloride Injection USP Local anesthetic injection for regional anesthesia and treatment of cardiac arrhythmias.
• Ampicillin and Sulbactam for Injection USP Combination antibiotic injection for susceptible bacterial infections, supplied to hospitals.
• Pantoprazole Sodium for Injection Proton pump inhibitor injection for gastroesophageal reflux disease and ulcer treatment in hospital settings.
• Plerixafor Injection Hematopoietic stem cell mobilizer injectable used for autologous transplantation in clinical settings.
• Gentamicin Injection, USP Aminoglycoside antibiotic for serious bacterial infections, supplied to hospital customers.
• Methocarbamol Injection, USP Muscle relaxant injection at 1000mg/10mL (100mg/mL) single dose vial; subject to voluntary nationwide recall.

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Others

• Hospira (Pfizer CentreOne / Pfizer Injectables): Hospira, now part of Pfizer, is a historically dominant US generic injectable franchise with deep GPO contracts and a very broad hospital portfolio. Closely comparable in product category and channel strategy, though substantially larger and more diversified across branded and generic pharmaceuticals.

Broad incumbents

• Aurobindo Pharma: Aurobindo Pharma is the Indian parent group of Eugia US and one of the largest generic pharmaceutical manufacturers globally, with extensive sterile injectable manufacturing capacity. Provides the manufacturing and API foundation for Eugia US and serves as a closely related but much larger entity.
• Sandoz: Sandoz is the global generics division of Novartis and a leading manufacturer of sterile injectable generics with extensive US presence. Direct overlap in generic injectable molecules and institutional channel, but operates at vastly larger scale and broader geographic footprint.
• Fresenius Kabi: Fresenius Kabi is one of the largest global manufacturers of generic injectable pharmaceuticals, with a broad portfolio spanning anesthesia, anti-infectives, critical care, and nutrition. Overlaps significantly in product categories and GPO channel, but operates at global scale across multiple therapeutic verticals including IV solutions and clinical nutrition.
• Viatris: Viatris (formed from Mylan and Upjohn) is a major global generics manufacturer with a significant US hospital injectables portfolio including products like Daptomycin and other sterile injectables. Comparable in institutional channel and generic injectable category, though at much larger scale and broader product breadth.
• Teva Pharmaceutical Industries: Teva is one of the largest global generic pharmaceutical manufacturers with a substantial US injectable presence serving hospitals and GPOs. Overlaps in generic injectable molecules and institutional customers, though Teva operates at much greater scale across generics, specialty, and biologics.

Direct peers

• Hikma Pharmaceuticals: Hikma is a global generic pharmaceutical manufacturer with a large US injectable franchise selling broad portfolios of sterile injectable products to hospitals and GPOs. Comparable in therapeutic class coverage and GPO-driven commercial model, though at significantly larger scale.
• Amphastar Pharmaceuticals: Amphastar is a specialty generic injectable pharmaceutical company focused on injectable, inhalation, and intranasal products, including complex generics like enoxaparin and Amphotericin B Liposome. Direct overlap with Eugia US in short-supply injectable molecules and hospital-channel distribution makes it the closest mid-sized US generic injectable comparator.
• Sagent Pharmaceuticals: Sagent is a US-focused generic injectable company selling a broad portfolio of hospital injectables through GPOs and direct accounts. Closely comparable in channel strategy, product breadth, and target customer base of US health systems and independent hospitals.
• American Regent: American Regent is a US specialty injectable manufacturer focused on hospital-administered injectables including iron products, vitamins, and specialty injectables. Overlaps in channel (hospital and GPO) and product complexity, with similar mid-sized positioning in the US injectable market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/auromedics-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Auromedics Pharma